Radiology Journals

Radiology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Delaloye AB et al. – In patients with low or minimal residual tumor burden after first–line chemotherapy of advanced FL, whole–body and bone marrow exposure after 90Y–ibritumomab tiuxetan consolidation showed a significant positive correlation with progression–free survival, whereas dosimetric data could not predict hematologic toxicity.

Exclusive Author Commentary
Angelika Bischof Delaloye , 11/10/09

Whole-body or bone marrow does and PFS correlated negatively with body weight, suggesting that patients in PR or CR with weight exceeding 80 kg might not receive an adequate radiation dose by the arbitrarily determined maximal activity of 1184 MBq.

Today in Radiotherapy (XRT)...keeping you current

Radiosurgery and whole brain therapy in the treatment of brainstem metastases
Clinical and Translational Oncology, 11/25/09

A multidimensional examination of correlates of fatigue during radiotherapy
Cancer, 11/25/09

N2 Disease in Patients With Head and Neck Squamous Cell Cancer Treated With Chemoradiotherapy
Archives of Otolaryngology, 11/25/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address